List of Fosrenol drug patents

Fosrenol is owned by Takeda Pharms Usa.

Fosrenol contains Lanthanum Carbonate.

Fosrenol has a total of 4 drug patents out of which 0 drug patents have expired.

Fosrenol was authorised for market use on 24 September, 2014.

Fosrenol is available in powder;oral dosage forms.

Fosrenol can be used as reduction of serum phosphate in patients with end stage renal disease.

The generics of Fosrenol are possible to be released after 01 December, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(1 year, 6 months from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(1 year, 6 months from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: POWDER;ORAL

How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage

FOSRENOL family patents

14

United States

7

Japan

6

European Union

5

Denmark

4

Australia

4

Poland

4

Spain

4

Cyprus

4

Slovenia

4

Portugal

4

China

4

Canada

3

Korea, Republic of

3

Brazil

3

EA

2

Austria

2

Germany

2

Hungary

2

South Africa

2

Norway

1

Hong Kong

1

Finland

1

Israel

1

Mexico

1

IB

1

Argentina

1

Peru

1

Singapore

1

Iceland

1

New Zealand

1

Czech Republic

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in